Cargando…
非小细胞肺癌EGFR基因靶向治疗研究进展
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought great clinical benefit to patients with EGFR-sensitive mutations. With the deepening of clinical and basic research, EGFR-TKIs have received more and more attention. In this review, we summarize the latest research...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973286/ https://www.ncbi.nlm.nih.gov/pubmed/28103975 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.01.09 |